Business
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE(TM) (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcino...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"\n \n \n \n Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP-COLOR:; VERTICAL-ALIGN: TOP; BORDER-LEFT-COLOR:; BORDER-BOTTOM-COLOR:; PADDING-LEFT:0.50em; BORDER-RIGHT-COLOR:; PADDING-RIGHT:0.50em\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnml80{\nMARGIN-LEFT:6.67em; MARGIN-TOP:0em; MARGIN-BOTTOM:0em\n}\n.prnbcc{\nBORDER-TOP-COLOR:; BORDER-COLLAPSE: COLLAPSE; BORDER-LEFT-COLOR:; BORDER-BOTTOM-COLOR:; BORDER-RIGHT-COLOR:\n}\n \n \n \n \n \n \n PR Newswire\n \n \n \n \n \n XIPERE™ is the First and Only Medicine to be Approved in\n \n the United States\n \n for Delivery via Suprachoroidal Injection, a Method Designed to Facilitate Targeted Delivery of Therapeutic Agents to the Retina and Choroid\n \n \n \n \n LAVAL, QC\n \n and\n \n ALPHARETTA, Ga.\n \n ,\n \n Oct. 25, 2021\n \n /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (\"Bausch Health\"), and Clearside Biomedical, Inc. (Nasdaq: CLSD) (\"Clearside\"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS\n \n ®\n \n ), today announced that the U.S. Food and Drug Administration (FDA) has approved XIPERE™ (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation\n \n 1\n \n .\n \n \n \"With this FDA approval, XIPERE™ is the first and only therapy available in\n \n the United States\n \n that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, which is the leading cause of vision loss in people with uveitis\n \n 2\n \n . The utilization of the suprachoroidal space provides targeted delivery and compartmentalization of medication,\" said\n \n Joseph C. Papa\n \n , chairman and CEO,\n...